We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Injectable Therapy May Avert Rotator Cuff Injuries

By HospiMedica International staff writers
Posted on 25 Dec 2013
An injectable compound under development could inhibit the breakdown of the supraspinatus tendon, a rotator cuff tendon that is commonly torn in sports. More...


Researchers at Georgia Tech (Atlanta, USA) and Emory University (Atlanta, GA, USA) are conducting a study to develop improved regenerative medicine strategies to aid repair of tendinopathic tissues. Since one of the hallmarks of tendinopathy is disruption of extracellular matrix (ECM), and particularly collagen, the researcher set out to test which classes of ECM proteases are involved in the tissue degeneration, and develop treatments to deliver inhibitory agents for these enzymes to reduce pathology progression and improve healing.

The central hypothesis of the researchers is that long-term regulation of protease activity in tendinopathy using a protease inhibitor will result in greater tendon tissue structure and mechanical properties. To do so, proteases and inhibitors related to ECM degradation will be tested in vivo in a rat supraspinatus tendon overuse model. The researchers hope to develop a controlled, injectable carrier to achieve local, sustained release of protease inhibitors. The researchers will also study the histology and mechanics of the tendons after healing.

“Normally people focus on treating tendon injuries after the tear has occurred, but we’re focusing on a much earlier stage in the disease,” said lead researcher associate professor Johnna Temenoff, PhD, of the department of Biomedical Engineering. “This is the first time that an injectable therapy specifically designed to interact with tissue at an early disease state has been attempted for this particular tendon injury.”

“We’re studying enzymes that are known to chew up the collagen, and we’re looking at then delivering inhibitors to those enzymes in a local injection in the tendon to try to stop the degradation,” added Dr. Temenoff. “We’re studying the disease in the shoulder, but it’s the same disease that causes tennis elbow, Achilles injuries, and jumper’s knee. It’s the same process, just in different tendons in the body.”

Tendinopathy is a common disorder resulting from repetitive motion in the workplace or during athletic activity that can cause severe pain and long-term disability due to tendon damage in the rotator cuff, a collation of four tendons made of collagen.

Related Links:

Georgia Tech
Emory University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.